
Immutep Ltd (IMMP) Stock Forecast & Price Target
Immutep Ltd (IMMP) Analyst Ratings
Bulls say
Immutep is well-positioned for success with their diversified product pipeline and strong leadership, making them a promising investment opportunity for the long-term. However, investors should be aware of potential risks related to stock market volatility and regulatory approval challenges. Overall, with expected positive results from their Phase 3 and Phase 2b trials, Immutep has the potential for significant growth in the future.
Bears say
Immutep is highly reliant on the FDA's pace of evaluating new drugs and their willingness to approve them, making it risky and dependent on external factors. Their positioning as a complementary agent rather than a direct competitor could negatively impact market potential, and there is confusion among experts regarding the drug's mechanism. Additionally, the clinical trials for both NSCLC and HNSCC have small sample sizes, and the data should be interpreted with caution.
This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.
Immutep Ltd (IMMP) Analyst Forecast & Price Prediction
Start investing in Immutep Ltd (IMMP)
Order type
Buy in
Order amount
Est. shares
0 shares